This technology describes the use of nucleoside triphosphate diphosphohydrolases (NTPDase8) for the treatment of liver ischemia-reperfusion injury.
Liver ischemia-reperfusion (I/R) injury occurs when the blood supply to the liver is temporarily disrupted and then restored, causing significant hepatic parenchymal damage. This injury frequently occurs during liver transplantation, substantive liver resections, and following trauma. The pathogenesis of liver I/R injury is complex, and involves a cascade of cellular and molecular events that ultimately lead to tissue damage. Despite the long-term implications of this injury, there are limited treatment options that target the molecular events leading to liver I/R tissue damage.
This technology describes the administration of NTPDase8 for the treatment of liver ischemia-reperfusion injury. NTPDase8 serves a protective role in the liver by critically suppressing inflammatory and metabolic responses to liver ischemia-reperfusion (I/R) injury. By modulating the extracellular levels of purine nucleotides and nucleosides, NTPDase8 reduces hepatic injury after I/R. Exogenous administration or endogenous overexpression of NTPDase8 therefore represents a strategy for preventing or treating liver I/R injury.
This technology has been validated in models of liver I/R injury in vivo.
Patent Pending (WO/2026/183317)
IR CU25127
Licensing Contact: Kristin Neuman
